Diabetes drugs and weight loss - Mayo Clinic
Nov 14, 2024 · Benefits beyond weight loss. Along with helping to control blood sugar and boosting weight loss, GLP-1 agonists and SGLT-2 inhibitors seem to have other health benefits. Research has found that some of these medicines may lower the risk of certain serious health conditions, such as kidney disease, heart disease, heart failure and stroke.
Semaglutide (subcutaneous route) - Mayo Clinic
Oct 1, 2024 · Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide injection is also used together with diet and exercise to help lose weight and keep the weight off in patients with at least one weight-related medical condition. This medicine is available only with your doctor's prescription.
Use of weight-loss pharmacotherapy in patients with cirrhosis and …
Aug 17, 2021 · The four weight-loss medications currently approved by the FDA for treatment of obesity are orlistat, phentermine-topiramate, naltrexone-bupropion and liraglutide. Although some society guidelines have endorsed the use of these medications in patients with cirrhosis or in liver transplant recipients, they have not yet been widely used in this ...
Management of obesity within hepatology clinics - Mayo Clinic
Dec 12, 2023 · Glucagon-like peptide 1 (GLP-1) receptor agonists. These agents can lead to significant weight loss. According to Dr. Watt, developing a solid understanding of how the various GLP-1 receptor agonists differ from one another may help clinicians choose the most appropriate agent for an individual patient. The Hepatology article contains a ...
Prescription weight-loss drugs: Can they help you? - Mayo Clinic
Oct 29, 2022 · Prescription weight-loss drugs that you can use for more than 12 weeks, called long-term use, lead to major weight loss compared with an inactive treatment that doesn't use medicine, called a placebo. The combination of weight-loss medicine and lifestyle changes leads to greater weight loss than do lifestyle changes alone.
Liraglutide (subcutaneous route) - Mayo Clinic
Oct 1, 2024 · This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist. Liraglutide injection is also used together with a reduced-calorie diet and proper exercise to help patients with obesity lose weight. This medicine is available only with your doctor's prescription.
Alli weight-loss pill: Does it work? - Mayo Clinic
Apr 9, 2024 · Clinically meaningful weight loss, generally defined as 5% or more of body weight, means that there is enough weight loss to begin lowering the risk of heart disease, diabetes and other diseases. People who ate a calorie-restricted diet, exercised regularly and took Alli lost an average of 5.7 pounds (2.6 kilograms) more in one year than did ...
Impact of ESG on weight loss, gastric emptying, gastric motility ...
Feb 11, 2023 · Greater GE delays at three months were associated with greater weight loss at three, six and 12 months. The percentage total body weight loss was significantly greater in the ESG group than in the LS interventions group at three, six and 12 months. GM was preserved, and fasting ghrelin, GLP-1 and PYY significantly increased 18 months after ESG.
HCG diet: Is it safe and effective? - Mayo Clinic
Jun 4, 2024 · HCG stands for human chorionic gonadotropin. It's a hormone made in the body during pregnancy. Lab-made HCG is added to some weight-loss products that are sold without a prescription. The U.S. Food and Drug Administration (FDA) warns against using these products. The HCG diet combines these weight-loss products with a very low-calorie eating plan.
Tirzepatide (subcutaneous route) - Mayo Clinic
It is used together with diet and exercise to help control your blood sugar. Tirzapatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide injection is also used to help lose weight and keep the weight off in patients with obesity caused by certain conditions.